Inspire Medical (INSP) Jumps to 3-Month High on Bullish Coverage, PT Upgrade

We recently published 10 Stocks Boasting 10-42% Gains. Inspire Medical Systems, Inc. (NYSE:INSP) is one of the best-performing stocks on Tuesday.

Inspire Medical soared to a new three-month high on Tuesday, as investors took path from an investment firm’s bullish coverage and higher price target for the stock.

At intra-day trading, the stock surged to a three-month high of $138.74 before trimming gains to finish the session just up by 11.17 percent at $130.39 apiece.

In a market note, Wolfe Research issued an “outperform” rating for Inspire Medical Systems, Inc. (NYSE:INSP), an upgrade from “peer perform” previously, alongside a price target of $180. The fair value assessment showed a 38 percent upside potential from its latest closing price.

According to Wolfe, the revision reflected updates to the 2026 final outpatient payment for Medicare, which moved CPT code 64568—the vagus nerve stimulation code, which now applies to Inspire Medical Systems, Inc.’s (NYSE:INSP) technology—to the new APC 1580 payment category. Such a change would ramp up Medicare payments to hospitals for Inspire Medical procedures to $45,000 from $30,000 previously.

In other recent news, Inspire Medical Systems, Inc. (NYSE:INSP) announced a net income of $9.9 million for the third quarter of the year, or a 46 percent decline from the $18.5 million in the same period last year.

Revenues, however, were higher by 10.5 percent to $224.5 million from $203.19 million year-on-year, thanks to a 9 percent growth in revenues from its US operations, at $214.4 million.

For the full-year 2025, the company maintained its revenue guidance of $900 million to $910 million, or an implied growth of 12 to 13 percent year-on-year.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.